Status:
UNKNOWN
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborating Sponsors:
University of Ibadan
University of Malawi
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Although psychotic disorders typically affect less than 1% of the population, they are a significant cause of disability worldwide. Psychotic symptoms such as hallucinations, delusions and suicidal id...
Detailed Description
Recognising the need for a framework for interventions to support people with psychosocial disabilities in LMICs, the WHO's 2010 CBR Guidelines included a special supplement on mental health, which dr...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Participants with lived experience of psychosis must:
- Be consenting/assenting adults (age 18+)
- Be able to speak one of the main study languages: English, Chichewa, Krio, Shona, Yoruba
- Live within the pilot study area
- Have a current or past diagnosis of schizophrenia or other primary psychotic disorder, bipolar or depressive disorder with psychotic symptoms, or a maternal mental health or behavioural disorder with psychotic symptoms, as per the World Health Organisation's International Classification of Diseases Version 11 (see full list of eligible diagnoses, below).
- For participants recruited from within the health care system, diagnosis will be confirmed from health records. For those identified in the community, a research worker will administer the World Health Organisation's Composite International Diagnostic Interview (WHO CIDI) screening tool for psychosis.
- The following diagnoses are eligible for inclusion:
- Schizophrenia (6A20)
- Schizoaffective disorder (6A21)
- Schizotypal disorder (6A22)
- Acute and transient psychotic disorder (6A23)
- Delusional disorder (6A24)
- Other specified (6A2Y) or unspecified (6A2Z) primary psychotic disorder
- Bipolar type I disorder with psychotic symptoms (6A60.1, 6A60.5, 6A60.7, 6A60.A)
- Bipolar type II disorder with psychotic symptoms (6A61.3, 6A61.5)
- Single episode depressive disorder with psychotic symptoms (6A70.2, 6A70.4)
- Recurrent depressive disorder with psychotic symptoms (6A71.2, 6A71.4)
- Mental or behavioural disorder associated with pregnancy, childbirth or the puerperium, with psychotic symptoms (6E21)
- Exclusion Criteria:
- People who are currently homeless, for logistical reasons; the SUCCEED intervention relies on PSWs and CSWs being able to regularly contact participants, including for home visits.
- People with secondary psychotic syndromes (6E61), as these are considered to be the direct consequences of physical health conditions as opposed to mental health conditions.
- People diagnosed with a substance-induced psychotic disorder (6C40.6-6C47.6), as recovery from substance use conditions is a specialist area outside the scope of the SUCCEED intervention under development.
Exclusion
Key Trial Info
Start Date :
July 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06007105
Start Date
July 18 2023
End Date
January 31 2024
Last Update
August 23 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kamuzu University of Health Sciences
Blantyre, Southern Region, Malawi, 0000
2
University of Ibadan
Ibadan, Oyo State, Nigeria, 0000
3
University of Makeni
Makeni, Northen Province, Sierra Leone, 0000
4
University of Zimbabwe
Harare, North East, Zimbabwe, 0000